Open Access |Therapeutic Brief
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The antidiabetic drug acarbose suppresses age-related lesions in C57BL/6 mice in an organ dependent manner
*Corresponding author: Warren Ladiges
Mailing address: Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Received: 28 May 2021 / Accepted: 12 June 2021
Acarbose (Acb) is an antidiabetic drug used to reduce blood glucose by inhibiting the conversion of complex carbohydrates into simple sugars. It has also shown promise as an anti-aging drug by increasing lifespan in mice but studies have not been reported on the effects of short-term treatment in aging mice. To address this question, 20-month-old C57BL/6 male and female mice were given a standard diet, or a diet supplemented with 1000 ppm Acb for 3 months. After this period, mice were assessed for age-related lesions as readouts for the delay in the progression of aging. Results showed there was a significant decrease in lesions of the heart and kidney in mice treated with Acb suggesting that Acb can suppress cardiac and renal pathology associated with increasing age.
Age-related lesions, acarbose, aging intervention, geropathology
Aging is a complex process and affects many organs in the body, so multiple pathways need to be targeted to combat or slow the effects of aging. Acarbose (Acb) is a well-known anti-diabetic drug for type 2 diabetic patients. It has been shown to decrease plasma glucose levels and cholesterol levels by the reversible inhibition of membrane-bound intestinal alpha-glucosidase and pancreatic alpha-amylase, two enzymes needed to digest complex carbohydrates . Recently, Acb has been shown to increase median and maximum life-span in mice, when treated starting at 4 months of age  or starting at 8 months of age , with a more pronounced effect in males than females. Aging increases the risk factor for cardiovascular diseases , kidney impairment, lung diseases  and liver diseases . It was therefore of interest to see if Acb might reduce age-related damage to organs in aging mice. Male and female C57BL/6 mice were used, 12 in each cohort. The experimental group was fed Acb (Cayman Chemical Co., Ann Arbor, MI) at 1000 ppm in their diet (prepared by TestDiet, Inc, a division of Purina Mills, Richmond, IN), while the control group was fed an identical diet without medication for 3 months starting at 20 Aging Pathobiology and Therapeutics 2021; 3(2): 41-42 41 DOI: 10.31491/APT.2021.06.056 months of age. After this period, mice were euthanized and tissues collected and slides of heart, lungs, liver and kidney were read and scored for age-related lesions using the geropathology grading platform as described . The results indicate that age-related lesions in the heart (Figure 1A) and kidney (Figure 1B) were significantly less in the Acb treated group compared to the control group for both males and females. There was no significant difference in lesion severity in the liver (Figure 1C) or lungs (Figure 1D) between treated and control mice. These observations suggest that Acb can potentially be used to decrease the risk of cardiac and renal lesions associated with aging. Type 2 diabetes is associated with kidney and heart failure . Decreasing risk of heart and kidney disease by Acb is consistent with this observation. Hence, Acb could potentially be used to decrease the risk of renal and cardiac diseases for people with a family history of these conditions. Further studies would be of interest to see the effects of acarbose in combination with other drugs like rapamycin, which has been shown to decrease pathological lesions in the lungs and liver, as well as the kidneys, in aging mice .
Figure 1. Male and female 57BL/6 mice, 20 months of age, were fed a diet containing 1000 PPM acarbose or a control diet without acarbose for three months. Tissues were collected and scored for age-related lesions. Mice fed the acarbose diet had decreased lesion scores in the heart and kidney compared to mice fed the control diet (A and B), but no differences were seen in the liver or lungs (C and D). *p ≤ 0.05.
Supported in part by R56 AG058543 and R01 AG057381 (Ladiges PI).
Conflict of interest
The authors declare no conflict of interest.
1. Balfour J A, McTavish D. Acarbose. Drugs, 1993, 46(6): 1025-1054.
2. Harrison D E, Strong R, Allison D B, et al. Acarbose, 17‐α‐ estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging cell, 2014, 13(2): 273-282.
3. Harrison D E, Strong R, Alavez S, et al. Acarbose improves health and lifespan in aging HET3 mice. Aging Cell, 2019, 18(2): e12898.
4. Steenman M, Lande G. Cardiac aging and heart disease in humans. Biophysical reviews, 2017, 9(2): 131-137.
5. O’Sullivan E D, Hughes J, Ferenbach D A. Renal aging: causes and consequences. Journal of the American Society of Nephrology, 2017, 28(2): 407-420.
6. Rojas M, Mora A L, Kapetanaki M, et al. Aging and lung disease. Clinical impact and cellular and molecular pathways[J]. Annals of the American Thoracic Society, 2015, 12(12): S222-S227.
7. Kim H, Kisseleva T, Brenner D A. Aging and liver disease. Current opinion in gastroenterology, 2015, 31(3): 184.
8. Snyder J M, Snider T A, Ciol M A, et al. Validation of a geropathology grading system for aging mouse studies. GeroScience, 2019, 41(4): 455-465.
9. Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Progress in cardiovascular diseases, 2019, 62(4): 298-302.
10. Ladiges W, Snyder J M, Wilkinson E, et al. A new preclinical paradigm for testing anti-aging therapeutics. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 2017, 72(6): 760-762.